rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

LivaNova PLC -

LIVN · Nasdaq

Health CareMedical DevicesIn trend

LIVN stood above a rising 150-day average in 51 of the last 52 weekly readings, including each of the last 24 weeks. It is 4.8% above that average now. Medical Devices: 27% of its 181 stocks in an uptrend (−7 points in four weeks); Health Care: 26% (−10 points in four weeks).

Statistics

Rotation
In trend
Weeks in an uptrend
24 in a row
Industry in uptrend
27% -7 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$2.1M
Officials’ trades on record
0
Institutions holding
280 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 51 of 52 weeks.

20 Apr – 19 Oct
19%29%40%Apr 26Jun 26Jul 26Sep 26Oct 26

Medical Devices: A minority of its stocks are in an uptrend and the share has been slipping. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$887K$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months7
Buyers · sellers0 · 3
WhoDidSharesTraded
Francesco BianchiDirectorsold3,500at $78.0110 Sep 2026filed 14 Sep 2026
Brooke StoryDirectorsold2,300at $81.424 Sep 2026filed 8 Sep 2026
Francesco BianchiDirectorsold1,650at $79.7231 Aug 2026filed 2 Sep 2026
Ahmet TezelChief Innovation Officersold2,675at $77.7411 Aug 2026filed 13 Aug 2026
Francesco BianchiDirectorsold1,200at $80.1915 Jun 2026filed 17 Jun 2026
Francesco BianchiDirectorsold1,800at $75.7526 May 2026filed 27 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders280+10 on the quarter
New · exited54 · 43
Reported value$4.8B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 20267,565,342$622.1M+426,434+6.0%
PRIMECAP MANAGEMENT COreduced · filed 14 Aug 20264,168,377$342.8M-38,675−0.9%
FMR LLCadded · filed 13 Aug 20263,147,068$258.8M+480,394+18.0%
Hood River Capital Management LLCadded · filed 14 Aug 20262,565,477$211.0M+1,928,937+303.0%
AQR CAPITAL MANAGEMENT LLCreduced · filed 14 Aug 20262,356,191$191.0M-138,181−5.5%
Invesco Ltd.added · filed 14 Aug 20262,237,319$184.0M+613,110+37.7%
Artisan Partners Limited Partnershipadded · filed 13 Aug 20262,224,763$182.9M+101,947+4.8%
STATE STREET CORPadded · filed 7 Aug 20262,165,863$178.1M+93,184+4.5%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20262,013,774$165.6M+218,839+12.2%
DIMENSIONAL FUND ADVISORS LPadded · filed 11 Aug 20261,845,285$151.7M+19,037+1.0%
31 Mar 2023 – 30 Jun 2026
174225276Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Anne M. Liddy Company insiderChief Legal Officer · last 15 Sep 20260 · 0
Francesco Bianchi Company insiderDirector · last 10 Sep 20260 · 8
Brooke Story Company insiderDirector · last 4 Sep 20260 · 2
Ahmet Tezel Company insiderChief Innovation Officer · last 11 Aug 20260 · 1
Donald Zurbay Company insiderDirector · last 15 Jun 20260 · 0
James Christopher Barry Company insiderDirector · last 15 Jun 20260 · 0
Jette Nygaard-Andersen Company insiderDirector · last 15 Jun 20260 · 0
Peter M. Wilver Company insiderDirector · last 15 Jun 20260 · 0
Seng Stacy Enxing Company insiderDirector · last 15 Jun 20260 · 0
Susan M. Podlogar Company insiderDirector · last 15 Jun 20260 · 0
Todd C. Schermerhorn Company insiderDirector · last 15 Jun 20260 · 0
William A. Kozy Company insiderDirector · last 15 Jun 20262 · 0

Same industry

RCEL Avita MedicalLeading+100%
HAE HaemoneticsLeading+48%
ATRC AtriCureLeading+47%
HTFL HeartflowLeading+47%

Distance from each stock’s own 150-day average.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202567.7%
Operating profit marginFY 2025 · to 31 Dec 202514.4%
Free cash flow marginFY 2025 · to 31 Dec 202512.5%
Return on capital employedFY 2025 · to 31 Dec 202511.1%
Debt to equityFY 2025 · to 31 Dec 20250.34×
Research spendFY 2025 · to 31 Dec 202513.4%
Share count trendFY 2025 · to 18 Feb 20260.1%
Cash and equivalentsFY 2025 · to 31 Dec 2025$635.6M
Free cash flowFY 2025 · to 31 Dec 2025$173.3M

Analyst forecasts

No analyst forecasts yet.